CVS Caremark Expands Zepbound and Foundayo Coverage

CVS Caremark will expand its commercial formulary to include oral and injectable obesity treatments.

Expansion of Pharmacy Benefit Formularies

Pharmacy benefit manager CVS Caremark has announced updates to its commercial formularies that will significantly expand coverage for weight-loss medications. According to a CVS Health press release, the PBM will add Eli Lilly's new oral GLP-1 drug, Foundayo (orforglipron), and restore preferred status to Zepbound (tirzepatide). These updates, reported by Fierce Pharma, represent a major shift in response to the high patient demand for metabolic therapies.

Patients should mark their calendars for these key formulary milestones:

• June 1, 2026: Oral Foundayo joins the commercial formulary with the removal of its new-to-market block.
• July 1, 2026: Experimental Medicare Part D transition program cost caps may begin for qualifying members.
• October 1, 2026: Zepbound is officially restored to preferred status on CVS Caremark commercial plans.

Coverage Details for Oral Foundayo

Foundayo is a first-of-its-kind oral non-peptide GLP-1 receptor agonist (a small-molecule pill that mimics satiety hormones without requiring an injection pen). Joining the formulary on June 1, 2026, Foundayo offers a convenient daily option for patients who prefer pills over needles. CVS Health confirmed they are lifting the new-to-market restriction, meaning participating employer plans can begin covering the drug immediately.

Medical experts note that oral options could ease the global supply shortages of injection pens, helping more patients access consistent treatment. Patients should speak with their doctor to see if an oral option fits their medical profile.

Restoration of Preferred Status for Zepbound

In another major win for patients, CVS Caremark will restore Zepbound to its preferred commercial drug list on October 1, 2026. Zepbound is a dual GIP and GLP-1 receptor agonist that targets two separate hunger pathways to optimize weight reduction. As reported by Healthcare Dive, preferred status means patients will face lower copays and fewer prior authorization hoops.

This update gives patients insurance-backed access to highly effective weight care. It expands the range of tirzepatide options available to individuals looking to manage their long-term metabolic health.

Employer Opt-Ins and Coverage Variations

While CVS Caremark has added these medications to its standard formulary, actual coverage is not guaranteed for every patient. Healthcare Dive reminds patients that individual employers and plan sponsors decide whether to include weight-management benefits in their insurance packages. If an employer opts out of obesity coverage, the drugs will not be covered despite their preferred status.

Because coverage varies by employer, patients should check their benefits portal or contact their HR department. You can also check if they qualify for covered treatments and see what plans are accepted by clinical partners.

Financial and Access Implications for Patients

CVS Health stated that eligible patients with commercial coverage could pay as little as $25 per month for Zepbound and Foundayo, depending on manufacturer co-pay cards. Additionally, Managed Healthcare Executive reported that experimental Medicare transition programs starting July 1, 2026, may offer cost caps for certain seniors. CVS Caremark also confirmed that Wegovy will remain preferred, ensuring multiple covered pathways for patients.

To avoid unexpected expenses, always verify your plan's specific deductible and prior authorization requirements. A quick check with your PBM can clarify your final out-of-pocket costs before you visit the pharmacy.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.